Biotech Values

[Bickema]

That is the goal. Even a small royalty on sales of Botox in certain indications could be worth a lot to RVNC.

if this turns out to be true then this would be a major oversight by Allergan considering Revance paid only $2 million upfront.

Seems wishful thinking to think Allergan could make such a mistake after dominating the Botulinum Toxin market for so long, one must think they have been well aware of these patents for some time and had no inclination to purchase them no?